Tuesday , January 16 2018
Home / Biosimilars / Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Check Also

Mylan and Momenta Announce Development Strategy for Proposed Biosimilar to Eylea

CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Jan. 3, 2018 /PRNewswire/ — Momenta Pharmaceuticals, Inc. …